3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Motor Activity
4
Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Obesity
2
Colorectal Neoplasms
2
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Skin Neoplasms
1
Sarcopenia
1
Renal Insufficiency, Chronic
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Overweight
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Locally Advanced Head and Neck Squamous Cell Carcinoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Inflammation
1
Hematopoietic and Lymphatic System Neoplasm
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
29
pembrolizumab
20
Cisplatin
20
Magnetic Resonance Spectroscopy
17
Specimen Handling
16
Mitomycin
10
enfortumab vedotin
9
durvalumab
9
Cystoscopy
9
avelumab
8
Nivolumab
8
Fluorouracil
8
Carboplatin
8
Radiation
7
Cystectomy
6
atezolizumab
5
Transurethral Resection of Bladder
5
Radiotherapy
5
Mitozytrex
5
Docetaxel
5
Biopsy
5
tremelimumab
4
sacituzumab govitecan
4
erdafitinib
4
dehydroftorafur
4
Platinum
4
Immunoglobulin G
4
Disulfides
4
1,2-diaminocyclohexaneplatinum II citrate
4
disitamab vedotin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Resistance Training
×
90 days
×
Clear all
No trials found.